Patents by Inventor Thomas MCCANN, JR.

Thomas MCCANN, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11213403
    Abstract: Devices and methods are provided for optimized spinal fixation using additive manufacturing techniques to create implants with optimized structure for various surgical approaches, anatomies, etc. One exemplary embodiment includes a cage having an X-shaped connection that can bear a load during cage impaction. The cage can be additively manufactured to incorporate features such as variable wall thickness or material density to adjust properties of the cage, including load bearing capability, flexibility, radiolucency, etc. The cage can further include one or more of the connectors disposed between upper and lower endplates. In some embodiments, the cage can include a feature for coupling an insertion device thereto for introducing the cage into the body of a patient. In some embodiments, a plate can be appended to or integrally formed with a proximal end of the cage to assist with securing the cage to vertebral bodies.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: January 4, 2022
    Assignee: Medos International Sarl
    Inventors: Marc Müller, Thomas McCann, Jr., Luke Ice, William Miller
  • Patent number: 11147920
    Abstract: Systems and methods for diabetes management with automatic basal and manual bolus insulin control are presented. An exemplary system includes a delivery device, a glucose sensor, and a controller. The delivery device delivers insulin and the glucose sensor measures glucose levels of the subject. A basal insulin dose is calculated using a model predictive control algorithm and physiological data of the subject including desired glucose levels, amounts of the delivered insulin and the measured glucose levels. A manual bolus insulin dose is initiated by the subject. The manual bolus insulin dose is modified based on one or both of the model predictive control algorithm and the physiological data of the subject. A total insulin dose is determined based on the modified manual bolus insulin dose and the calculated basal insulin dose, and delivered to the subject.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: October 19, 2021
    Assignee: LifeScan IP Holdings, LLC
    Inventors: Daniel Finan, Thomas McCann, Jr.
  • Publication number: 20200289288
    Abstract: Devices and methods are provided for optimized spinal fixation using additive manufacturing techniques to create implants with optimized structure for various surgical approaches, anatomies, etc. One exemplary embodiment includes a cage having an X-shaped connection that can bear a load during cage impaction. The cage can be additively manufactured to incorporate features such as variable wall thickness or material density to adjust properties of the cage, including load bearing capability, flexibility, radiolucency, etc. The cage can further include one or more of the connectors disposed between upper and lower endplates. In some embodiments, the cage can include a feature for coupling an insertion device thereto for introducing the cage into the body of a patient. In some embodiments, a plate can be appended to or integrally formed with a proximal end of the cage to assist with securing the cage to vertebral bodies.
    Type: Application
    Filed: March 14, 2019
    Publication date: September 17, 2020
    Inventors: Marc Müller, Thomas McCann, JR., Luke Ice, William Miller
  • Publication number: 20180296757
    Abstract: Systems and methods for diabetes management with automatic basal and manual bolus insulin control are presented. An exemplary system includes a delivery device, a glucose sensor, and a controller. The delivery device delivers insulin and the glucose sensor measures glucose levels of the subject. A basal insulin dose is calculated using a model predictive control algorithm and physiological data of the subject including desired glucose levels, amounts of the delivered insulin and the measured glucose levels. A manual bolus insulin dose is initiated by the subject. The manual bolus insulin dose is modified based on one or both of the model predictive control algorithm and the physiological data of the subject. A total insulin dose is determined based on the modified manual bolus insulin dose and the calculated basal insulin dose, and delivered to the subject.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 18, 2018
    Inventors: Daniel FINAN, Thomas MCCANN, JR.